Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lineage Cell Therapeutics, Inc. LCTX

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for...


Recent & Breaking News (NYSEAM:LCTX)

BioTime Announces Second Quarter 2014 Results and Recent Developments

Business Wire August 12, 2014

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014

Business Wire August 11, 2014

BioTime, Inc. Subsidiary OncoCyte Corporation Expands Clinical Development of Bladder Cancer Diagnostic by Initiating a Large Multi-Site Clinical Trial

Business Wire July 31, 2014

Asterias Biotherapeutics Announces Live Investor Webcast

PR Newswire July 24, 2014

BioTime Announces Issuance of 14 Patents in the Fields of Regenerative Medicine, and Cancer Diagnosis and Therapy

Business Wire July 14, 2014

BioTime Subsidiary Asterias Biotherapeutics Raises $13.0 Million in Equity Financing

Business Wire June 17, 2014

BioTime Subsidiary Asterias Biotherapeutics Announces Investment by CEO

Business Wire June 17, 2014

BioTime Subsidiary Asterias Biotherapeutics Appoints Former Pfizer Senior Executive Pedro Lichtinger as President and Chief Executive Officer

Business Wire June 12, 2014

BioTime to Present at the Jefferies 2014 Global Healthcare Conference

Business Wire June 2, 2014

BioTime's Subsidiary Asterias Biotherapeutics, Inc. Announces a $14.3 Million Strategic Partnership Award from the California Institute for Regenerative Medicine

Business Wire May 30, 2014

BioTime's Subsidiary Asterias Biotherapeutics, Inc. Settles Patent Interference Proceedings

Business Wire May 28, 2014

BioTime Receives ISO 13485 Certification for Medical Devices

Business Wire May 28, 2014

BioTime's Subsidiary OncoCyte Corporation and Cornell University Enter License Agreement to Accelerate Lung Cancer Diagnostic Product Development

Business Wire May 27, 2014

Asterias Biotherapeutics, Inc. Launches New Website: Asteriasbiotherapeutics.com

Business Wire May 21, 2014

Asterias Biotherapeutics, Inc. to Present Phase I Clinical Data at the 17th Annual Meeting of the American Society of Gene & Cell Therapy

Business Wire May 13, 2014

BioTime Announces First Quarter 2014 Results and Recent Developments

Business Wire May 12, 2014

LifeMap Solutions, Inc. to Develop Mobile Health Products With Mount Sinai's Icahn School of Medicine

Business Wire May 7, 2014

BioTime Raises $6.4 Million in Equity Financing

Business Wire May 5, 2014

BioTime to Present at GTC Stem Cell Summit 2014

Business Wire April 24, 2014

BioTime, Inc. Announces Board Membership Changes and Management and Board Changes at Its Subsidiary Asterias Biotherapeutics, Inc.

Business Wire April 14, 2014